Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
1.770
-0.010 (-0.56%)
At close: Feb 11, 2026, 4:00 PM EST
1.790
+0.020 (1.13%)
After-hours: Feb 11, 2026, 4:47 PM EST
Editas Medicine Revenue
Editas Medicine had revenue of $7.54M in the quarter ending September 30, 2025, with 12,265.57% growth. This brings the company's revenue in the last twelve months to $46.38M, down -24.90% year-over-year. In the year 2024, Editas Medicine had annual revenue of $32.31M, down -58.64%.
Revenue (ttm)
$46.38M
Revenue Growth
-24.90%
P/S Ratio
3.26
Revenue / Employee
$188,549
Employees
246
Market Cap
173.27M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 32.31M | -45.81M | -58.64% |
| Dec 31, 2023 | 78.12M | 58.41M | 296.32% |
| Dec 31, 2022 | 19.71M | -5.83M | -22.83% |
| Dec 31, 2021 | 25.54M | -65.19M | -71.85% |
| Dec 31, 2020 | 90.73M | 70.20M | 341.93% |
| Dec 31, 2019 | 20.53M | -11.41M | -35.71% |
| Dec 31, 2018 | 31.94M | 18.21M | 132.64% |
| Dec 31, 2017 | 13.73M | 7.68M | 126.80% |
| Dec 31, 2016 | 6.05M | 4.42M | 271.58% |
| Dec 31, 2015 | 1.63M | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| C4 Therapeutics | 30.11M |
| Sol-Gel Technologies | 18.97M |
| Prelude Therapeutics | 10.50M |
| Cartesian Therapeutics | 1.09M |
| Molecular Partners AG | 856.30K |
EDIT News
- 23 days ago - Genflow Biosciences PLC Announces Directorate Change - Accesswire
- 3 months ago - Editas Medicine Announces Third Quarter 2025 Results and Business Updates - GlobeNewsWire
- 3 months ago - Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025 - GlobeNewsWire
- 4 months ago - Editas Medicine: Three Strikes And It's Out, Or Third Time's The Charm? - Seeking Alpha
- 4 months ago - Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress - GlobeNewsWire
- 4 months ago - Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences - GlobeNewsWire
- 5 months ago - Editas Medicine, Inc. - Special Call - Seeking Alpha
- 5 months ago - Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate - GlobeNewsWire